Alvea Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Employees
-
59
- Latest Deal Type
-
Out of Business
Alvea General Information
Description
Developer of vaccine platform intended to test a simple, adaptable, and scalable COVID-19 vaccine. The company's platform specializes in deploying medical countermeasures that fight infectious diseases and developing new vaccines against SARS-CoV-2 and its variants as step one in a plan, enabling people to strengthen humanity against future biological threats.
Contact Information
Website
www.alvea.bioCorporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Corporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Alvea Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 12-Oct-2023 | Completed | Out of Business | |||
| 1. Seed Round | 01-Aug-2022 | Completed | Clinical Trials - Phase 1 |
Alvea Signals
Alvea Acquisitions (1)
Alvea’s most recent deal was a Merger/Acquisition with Telis Bioscience.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Telis Bioscience | Merger/Acquisition | Drug Discovery |
Alvea FAQs
-
When was Alvea founded?
Alvea was founded in 2019.
-
Where is Alvea headquartered?
Alvea is headquartered in Cambridge, MA.
-
What is the size of Alvea?
Alvea has 59 total employees.
-
What industry is Alvea in?
Alvea’s primary industry is Biotechnology.
-
Is Alvea a private or public company?
Alvea is a Private company.
-
What is Alvea’s current revenue?
The current revenue for Alvea is .
-
How much funding has Alvea raised over time?
Alvea has raised $18.9M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process